首页> 外文OA文献 >Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy

【2h】

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy

机译：Her2-阴性激素受体阳性转移性乳腺癌患者维持贝伐单抗超过一线紫杉醇联合贝伐单抗的疗效：与激素疗法联合使用的疗效

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Alessandra Fabi; Michelangelo Russillo; Gianluigi Ferretti; Giulio Metro; Cecilia Nisticò; Paola Papaldo; Ferdinando De Vita; Giuliana D’Auria; Antonello Vidiri; Diana Giannarelli; Francesco Cognetti;
展开▼
作者单位

展开▼
年度 2012
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer [J] . Xue-Lian Chen, Feng Du, Ruo-Xi Hong, Chinese journal of cancer . 2016,第1期

机译：对于激素受体阳性和HER2阴性，转移性乳腺癌的患者，在一线基于卡培他滨的联合化疗后，激素治疗可能是比卡培他滨更好的维持治疗方法
2. Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer [J] . Xue-Lian Chen, Feng Du, Ruo-Xi Hong, Cancer Communications . 2016,第1期

机译：对于激素受体阳性和HER2阴性，转移性乳腺癌的患者，在一线基于卡培他滨的联合化疗后，激素治疗可能是比卡培他滨更好的维持治疗方法
3. A multicenter phase II study evaluating the efficacy of nivolumab plus paclitaxel plus bevacizumab triple-combination therapy as a first-line treatment in patients with HER2-negative metastatic breast cancer: WJOG9917B NEWBEAT trial [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：多中心期II研究评估Nivolumab Plus Paclitaxel Plus Bevacizumab三重组合疗法作为Her2阴性转移乳腺癌患者的一线治疗的疗效：WJOG9917B Newbeat试验
4. Correlation between development of hypertension and efficacy in metastatic colorectal cancer patients treated with bevacizumab [C] . Horinouchi Y., Sakurada T., Nakamura T., European Association for Clinical Pharmacology and Therapeutics . 2011

机译：北伐单抗治疗转移性结直肠癌患者高血压与疗效的相关性
5. Treatment Interruption and Discontinuation of Hormone Therapy in Hormone Receptor-Positive Breast Cancer Patients [D] . Mao, Daqin . 2020

机译：激素受体阳性乳腺癌患者中的治疗中断与激素治疗中的中断和停止
6. Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy [O] . Alessandra Fabi, Michelangelo Russillo, Gianluigi Ferretti, 2012

机译：Her2-阴性激素受体阳性转移性乳腺癌患者维持贝伐单抗超过一线紫杉醇联合贝伐单抗的疗效：与激素疗法联合使用的疗效
7. Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy [O] . Fabi Alessandra, Russillo Michelangelo, Ferretti Gianluigi, 2012

机译：维持贝伐单抗超过一线紫杉醇加贝伐单抗治疗Her2阴性激素受体阳性转移性乳腺癌患者：与激素治疗联合应用的疗效

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy

著录项

引文网络

相似文献

相关主题

期刊订阅